Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings Cover

.blurhash-client-img { display: none !important; }

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Acta Medica Bulgarica

Volume 48 (2021): Issue 3 (October 2021)

By: D. Nikolova, A. Yordanov and A. Radinov

Open Access

|Oct 2021

Authors

D. Nikolova

Department of Medical Genetics, Medical University – Sofia, Bulgaria

A. Yordanov

University Hospital for Active Treatment “Sv. Ivan Rilski” – Sofia, Bulgaria

A. Radinov

University Hospital for Active Treatment “Sv. Ivan Rilski” – Sofia, Bulgaria

DOI: https://doi.org/10.2478/amb-2021-0030 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750

Journal RSS Feed

Language: English

Page range: 19 - 25

Submitted on: Jan 29, 2021

Accepted on: Feb 6, 2021

Published on: Oct 22, 2021

Published by: Sofia Medical University

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

Azacitidine (AZA, Vidaza®),

blood count parameters,

cytogenetic findings

Related subjects:

Basic medical science,

Clinical medicine,

Clinical medicine, other

© 2021 D. Nikolova, A. Yordanov, A. Radinov, published by Sofia Medical University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 48 (2021): Issue 3 (October 2021)Next article